Enfortumab vedotin (EV) is a breakthrough antibody-drug conjugate (ADC) designed to treat metastatic urothelial carcinoma. While clinical outcomes have improved, this agent frequently induces metabolic emergencies like Refractory Diabetic Ketoacidosis. Consequently, managing these cases requires a deep understanding of the drug’s underlying pharmacokinetics when standard insulin infusions prove insufficient.

Mechanisms Behind Refractory Diabetic Ketoacidosis

EV targets Nectin-4 to deliver monomethyl auristatin E (MMAE), a potent cytotoxic agent. However, systemic exposure to MMAE often triggers extreme insulin resistance. In a recent clinical report, a 57-year-old man developed profound ketoacidosis that resisted conventional protocols. Furthermore, the persistence of the condition suggests that standard metabolic correction cannot overcome the ongoing toxicity of circulating MMAE. Therefore, clinicians must identify pathways to accelerate the elimination of the offending drug.

A Pharmacokinetic Approach to Treatment

The body primarily eliminates MMAE through metabolism by the cytochrome P450 (CYP) 3A4 enzyme and subsequent biliary excretion. Additionally, P-glycoprotein efflux pumps help limit tissue exposure. Given this metabolic profile, the medical team initiated pharmacologic enzyme induction to enhance MMAE clearance in the setting of Refractory Diabetic Ketoacidosis. This novel strategy aimed to reduce systemic toxicity rapidly. Consequently, the patient achieved resolution of ketoacidosis within 46 hours of starting the induction therapy. Moreover, this case demonstrates that tailored pharmacological interventions can improve outcomes when standard diabetic care fails.

Practical Implications for Clinicians

Monitoring blood glucose levels remains mandatory for all patients receiving EV. However, if ketoacidosis becomes refractory, providers should consider the patient's pharmacokinetic profile. Furthermore, early consultation with clinical pharmacists and toxicologists may facilitate the use of enzyme inducers. Ultimately, this informed approach provides a vital secondary strategy for managing life-threatening adverse events associated with modern antibody-drug conjugates.

Frequently Asked Questions

What makes enfortumab vedotin-associated DKA different from standard DKA?

DKA associated with enfortumab vedotin often presents with extreme insulin resistance due to the systemic effects of the MMAE component. Unlike typical DKA, it may not respond to standard doses of insulin, requiring a focus on drug clearance.

How does CYP3A4 induction assist in managing this condition?

Since MMAE is primarily metabolized by the CYP3A4 enzyme, inducing this enzyme can speed up the detoxification process. This reduces the duration of systemic exposure and helps resolve the underlying cause of the metabolic crisis.

Who should be most closely monitored for these complications?

Patients with pre-existing hyperglycemia, a high body mass index, or those receiving combination therapies like pembrolizumab should undergo frequent metabolic screening during EV treatment cycles.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Patel SK et al. Refractory Diabetic Ketoacidosis Associated with Enfortumab Vedotin: A Pharmacokinetic-Based Management Approach. Kidney360. 2026 Jun 15. doi: 10.34067/KID.0000001262. PMID: 42295856.

2. Heinrich RE, Caldwell M. New onset, refractory hyperglycemia with diabetic ketoacidosis after enfortumab vedotin treatment: a case report. J Maine Med Cent. 2023;5(2).

3. Matsui S, et al. Enfortumab Vedotin-Induced Diabetic Ketoacidosis and Acute Tubulointerstitial Nephritis Requiring Intensive Care. Case Rep Oncol. 2025;18:667-674.